Engflag

Calcigen D

Quick links to important sections

Calcigen D

Calcigen D_EN

Method of action: Compensating Calcium Deficiency, Mineral, Mineral Supplements, Regulating Calcium-Phosphorus Exchange, Replenishing Deficiency Of Calcium And Vitamin D3, Replenishing Mineral Deficiency, Vitamins

Treatment option: Pregnancy, Vitamin D Deficiency, Malnourishment, Osteomalacia, Osteoporosis, Alkaline Phosphatase

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Calcigen D

Property Description
Active ingredient Calcium Carbonate, Dihydrotachysterol (DHT)
Form Oral Solid Form (e.g., tablet) or Solution
Pharmacological Class Mineral Supplement and Vitamin D Analog / Anti-hypocalcemic Agent
Common Type Combination Product
Origin Synthetic (DHT) and Inorganic Salt (Calcium Carbonate)

Calcigen D: Identity and Pharmacological Class

Calcigen D is an oral combination medicine classified as a high-level Mineral Supplement and Vitamin D Analog, primarily functioning as an anti-hypocalcemic agent. The medicine is defined by its two principal active ingredients: the inorganic salt Calcium Carbonate and the synthetic derivative Dihydrotachysterol (DHT). This dual formulation is intended for systemic application to address deficiencies in the body's essential mineral balance.

The drug’s classification confirms its core purpose is to maintain and restore necessary calcium levels in the blood. The preparation is typically provided in an oral solid form for reliable intake.

Composition: Unique Attributes of Dihydrotachysterol

The active composition relies on Calcium Carbonate to supply the essential elemental calcium, while Dihydrotachysterol acts as a metabolic facilitator. Dihydrotachysterol is a secosteroid and a potent synthetic analog of Vitamin D. This synthetic derivative distinguishes itself from natural Vitamin D forms, such as cholecalciferol, by requiring a simpler metabolic activation pathway, occurring predominantly in the liver.

This streamlined process ensures a reliable systemic effect, which is particularly beneficial in contexts where natural Vitamin D activation might be impaired, such as issues with renal calcium regulation. The inclusion of this analog is a key differentiating factor from simple mineral supplements.

General Purpose as a Calcium Regulator

The general therapeutic purpose of Calcigen D is to act as a definitive calcium regulator, restoring stable levels of calcium by regulating overall calcium and phosphate metabolism. The combined action of the active ingredients facilitates the stimulus of intestinal absorption of minerals and supports the controlled mobilization of bone calcium. Its systemic effect is specifically focused on correcting the underlying state of hypocalcemia, a typical use scenario when mineral deficiencies are identified.

What side effects are possible with Calcigen D?

Possible Side Effects and Safety Information

The safety profile of Calcigen D is primarily characterized by the systemic effects related to its action as a calcium regulator, namely the risk of elevated calcium levels in the blood (hypercalcemia) and urine (hypercalciuria). These conditions, which are documented as uncommon adverse events, form the basis for most safety considerations associated with the medicine.

Official Adverse Reaction Groupings

Adverse reactions are officially categorized by the system affected, as documented in regulatory labeling. The most frequently cited effects are:

  • Metabolism and Nutrition Disorders: Hypercalcemia, Hypercalciuria, and loss of appetite (anorexia).
  • Gastrointestinal Disorders: Reactions such as nausea, vomiting, and constipation are documented.
  • Renal and Urinary Disorders: Increased thirst (polydipsia) and frequent urination (polyuria) are common signs, while nephrocalcinosis and renal insufficiency are cited as serious complications associated with prolonged exposure.
  • Nervous System Disorders: Documented effects include headache, fatigue, drowsiness, and confusion, often linked to the severity of hypercalcemia.

Serious Safety Considerations

The medicine is officially constrained by safety limitations. It is contraindicated (should not be used) in individuals with pre-existing conditions such as Hypercalcemia, Hypervitaminosis D, or Severe Renal Insufficiency. The regulatory profile also notes that the physiological effects of the Dihydrotachysterol component can persist for two or more months after cessation of treatment. For specific populations, the labeling mentions an increased risk of hypercalcemia in those with renal impairment and documents concerns in the pediatric population regarding potential effects on linear growth.

Overdose and Emergency Response

Calcigen D Overdose and when to seek help

The documented overdose profile for Calcigen D is centered on the consequences of severe and prolonged hypercalcemia (excessive calcium in the blood), resulting from the high potency of the Dihydrotachysterol component. The official regulatory classification for this overdose is potentially severe and life-threatening.

Initial manifestations of an overdose, as described in regulatory sources, include nonspecific symptoms such as anorexia, nausea, vomiting, headache, weakness, and excessive thirst (polydipsia) and urination (polyuria).

Severe outcomes documented in official labeling may include serious complications such as cardiac arrhythmias, hypertension, acute renal impairment or failure, and Central Nervous System effects like confusion, stupor, or coma. The regulatory profile notes that patients with pre-existing impaired renal function face an increased severity of risk.

Immediate medical attention is required for any suspected overdose event. Individuals exhibiting severe signs such as irregular heartbeat, profound confusion, or difficulty awakening must contact emergency services immediately.

Management is strictly symptomatic and supportive, as no specific antidote is known. Regulatory documents mandate hospitalization for monitoring, including frequent determination of serum calcium levels and Electrocardiographic (ECG) monitoring, until the risk of severe systemic consequences has passed.

Therapeutic Uses of Calcigen D

Calcigen D is a combination medicine generally used in the management of conditions related to systemic mineral imbalance, which supports stability across critical physiological and structural domains. This medication is applied in addressing symptomatic presentations linked to low calcium levels.

The therapeutic benefit of Calcigen D is considered relevant in addressing symptoms related to multiple physiological domains. It is commonly used in addressing symptomatic hypocalcemia and associated mineral imbalances in individuals diagnosed with Hypoparathyroidism, Osteomalacia, Rickets, and conditions like Renal Osteodystrophy. The medicine's use is often directed at relieving the symptoms of neuromuscular hyperexcitability—including muscle cramps, spasms, and the condition of tetany.

This supportive role is particularly relevant in situations involving heightened systemic burden. The medication helps manage the intensity of these symptom clusters, which supports general well-being during symptomatic phases and assists with maintaining functional stability.

Quick Fact: Relief for Neuromuscular Symptoms

Quick Fact: Relief for Neuromuscular Symptoms. Calcigen D is generally applied in addressing episodes where low calcium levels trigger involuntary muscle manifestations, providing supportive relief that helps manage the patient's overall symptom load.

Eligibility and Restrictions for Use

Official Eligibility Profile: Calcigen D

Regulatory authorities define strict boundaries for the use of Calcigen D, an oral medicine containing Calcium Carbonate and Dihydrotachysterol (DHT), primarily based on a patient’s existing mineral and physiological status.

Eligibility Scope Status as Stated in Regulatory Documents
Populations for whom use is contraindicated Patients with Hypercalcaemia (high blood calcium) or Hypervitaminosis D (vitamin D toxicity); women who are breastfeeding; and individuals with known hypersensitivity to the components.
Populations for whom use is allowed Adults and pediatric patients for its labeled indications, such as hypoparathyroidism and rickets, where specific dosing is established.
Pregnancy Eligibility Status Use is restricted (e.g., formerly Category C); only permitted when the potential benefit is explicitly deemed to outweigh potential risks to the fetus.
Condition-specific eligibility rules Use requires caution and surveillance in patients with impaired renal function, Sarcoidosis, and conditions that involve Hyperphosphatemia.

Eligibility-Related Restrictions: The eligibility constraints are directly linked to the drug's effect on calcium and vitamin D balance. Conditional use is applied to prevent adverse effects like soft tissue calcification, necessitating mandatory monitoring of serum mineral levels during treatment.

What should I know about interactions with other medicines?

The interaction profile for Calcigen D, containing Calcium Carbonate and Dihydrotachysterol (DHT), is structured around the potential for elevated calcium levels and altered drug exposure, as stated in government-approved regulatory documents.

Official Interaction Statements

Interaction Classification Interacting Substance/Category Official Regulatory Description
Contraindicated Other Vitamin D compounds/analogs (e.g., Calcitriol) High risk of additive hypercalcemia; severe toxicity risk.
Contraindicated Cardiac Glycosides (e.g., Digoxin) Hypercalcemia potentiates the toxic effects on the heart, increasing the risk of ventricular arrhythmias.
Clinically Significant Thiazide Diuretics (e.g., Chlorothiazide) Increased risk of hypercalcemia due to reduced renal calcium excretion.
Clinically Significant Bile Acid Sequestrants (e.g., Cholestyramine) May impair or decrease the absorption of the fat-soluble Dihydrotachysterol component.
Clinically Significant Enzyme Inducers (e.g., Phenytoin, Rifampicin) May reduce the effectiveness of Dihydrotachysterol by increasing its metabolic breakdown.

Additional Constraints and Notes

  • Magnesium-Containing Products: Concomitant use with magnesium-containing laxatives or antacids may increase the risk of hypermagnesemia, particularly in patients with renal impairment.
  • Timing Separation: Calcium Carbonate should be dosed separately from Iron supplements and other minerals to prevent interference with absorption.
  • Dietary Interference: Foods high in oxalic acid (e.g., spinach) or phytic acid (e.g., bran) may decrease calcium absorption by forming indigestible compounds.

Regulatory documents define the product's profile by strictly prohibiting combinations that enhance cardiac sensitivity or severely increase systemic calcium. Further constraints address necessary timing separation for minerals and substances that reduce the exposure of the active ingredients.

Mechanism of Action

How Calcigen D Works — Mechanism of Action

VDR Agonism and Increased Intestinal Calcium Uptake

This domain describes the primary role of the active vitamin component, Calcitriol, which acts as an agonist on the Vitamin D Receptor (VDR) in the small intestine. This molecular action triggers the production of calcium transport proteins, thereby increasing the absorption of dietary Ca^2+ into the bloodstream.

Homeostatic Regulation of Systemic Mineral Balance

This mechanism involves the integrated control of the Parathyroid Hormone (PTH)-Vitamin D axis across the kidney and parathyroid gland. By enhancing renal reabsorption of Ca^2+ and modulating PTH release, the mechanism contributes to the maintenance of normocalcemia (stable Ca^2+ levels in the blood), a state required for systemic cellular function.

Promotion of Bone Mineralization

This final step involves the synergistic delivery of the Ca^2+ substrate and the regulatory hormone to the bone tissue. The resulting elevated serum Ca^2+ and phosphate concentrations provide the necessary components for osteoblasts to deposit mineral crystals into the osteoid, directly facilitating the incorporation of calcium into the osteoid, which forms the basis of bone mass and rigidity.

Dosage and Administration Information

Calcigen D, an oral combination product containing Dihydrotachysterol (DHT) and Calcium Carbonate, is administered orally as a long-term therapeutic regimen. Its usage is highly individualized and is strictly controlled by blood test monitoring.

Administration and Dosage Regimens

The medicine is taken by the oral route, often available as a tablet, capsule, or a liquid solution. A crucial administration condition is the requirement for co-administration with an adequate source of elemental calcium, typically Calcium Carbonate. To optimize absorption, the calcium component should generally be consumed with food.

The dosage schedule is based on a daily frequency, often involving a higher initial dose for the DHT component followed by a maintenance dose. Typical adult dosing, for conditions like hypoparathyroidism, begins with 0.8 mg to 2.4 mg of DHT once daily for several days, transitioning to a maintenance range of 0.2 mg to 1 mg of DHT once daily. The supplemental elemental calcium is usually administered in divided doses throughout the day, often ranging from 1.0 g to 3.0 g daily.

Procedural Controls

Treatment follows a rigorous, laboratory-guided protocol to maintain serum calcium levels within a specific target range (e.g., 9 mg/ dL to 10 mg/ dL). The Dihydrotachysterol dosage may be adjusted at intervals of 4 to 8 weeks based on the patient's biochemical response. The dosage must be withheld immediately if hypercalcemia develops, emphasizing the necessity of continuous medical supervision for proper administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Trial Findings

Research has explored whether the compound's primary focus could influence pain by targeting specific neural pathways. The investigation focused on participants experiencing non-chronic pain. The components of Calcigen D—calcium and vitamin D—have been widely studied, with meta-analyses supporting their use in assessing fracture risk reduction in middle-aged and older adults. However, findings across all populations and outcomes have been inconsistent.

  • Pain Score Assessment: In clinical trials, studies have examined whether this medication might affect patient outcomes over a 12-week period. Research assessed the potential for changes in symptoms among the participant groups.
  • Tolerability Findings: The overall rate of reported side effects was assessed in the studied populations. Reported events included gastrointestinal distress and temporary fatigue. Studies did not assess participants with chronic conditions.

Dose and Related Studies

Dose-Ranging Research

Studies evaluated the effects of the higher dosage in participants with severe forms of the condition. Findings suggested that the frequency of dosing may influence the reported outcomes, though evidence remains limited. Research has compared this treatment to older methods in terms of outcomes that were reported and tolerability.

Pharmacokinetics (PK)

Studies have investigated the compound's potential to interact with the activity of the enzyme X. This research explores the compound's effect on biological processes related to mineral homeostasis. Research examined whether the combination of compounds could affect absorption.

  • Inflammation Studies: Studies investigated whether the drug might influence inflammation and assessed participant reports of symptom change within the first 48 hours of administration. Research is ongoing regarding the role of vitamin D in modulating immune and inflammatory responses.
  • Interaction Data: Studies explored potential interactions with supplements, specifically Vitamin D and Calcium, and found no statistically significant changes in absorption rates for the study population.

Key Studies & References

  1. Calcium and/or Vitamin D Supplementation for the Prevention of Fragility Fractures: Who Needs It? (Review discussing inconsistent findings)
  2. Vitamin D: Uses, Interactions, Mechanism of Action | DrugBank Online (Source for PK and enzyme interaction context)
  3. Immunomodulatory actions of vitamin D in various immune-related disorders: a comprehensive review

How should Calcigen D be stored and disposed of?

Calcigen D must be stored under specific conditions to maintain product stability, as defined by regulatory documents. The medication should be kept at Controlled Room Temperature in a cool, dry place, generally between 20°C and 25°C (68°F and 77°F). It is mandatory to protect the product from freezing and excessive moisture. The container must be kept tightly closed to ensure stability and should remain in its original packaging. For safety, the medicine must be stored out of the sight and reach of children. Expired or unused Calcigen D should be disposed of using a drug take-back program. If this is unavailable, it can be discarded in household trash after being mixed with an undesirable substance, following FDA guidelines for non-flush list medicines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagGermany

Equivalent of Calcigen D found in:

A-Z Index: